Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
- None.
- None.
A live webcast of the panel discussion will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. A replay of the webcast will be available for 30 days following each presentation.
About Rallybio
Rallybio (Nasdaq: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221212601/en/
Investor Contacts
Ami Bavishi
Head of Investor Relations and Communications
475-47-RALLY (Ext. 282)
abavishi@rallybio.com
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
Media Contact
Victoria Reynolds
Mission North
760-579-2134
rallybio@missionnorth.com
Source: Rallybio Corporation
FAQ
When will Steve Uden, M.D., CEO of Rallybio, participate in a panel discussion?
Where can the live webcast of the panel discussion be accessed?
How long will the replay of the webcast be available?
